A Rapid Review of Potential Drug Treatments for Children with COVID-19

Total Views: 254 | Total Downloads: 219


  • Khairun Nain Nor Aripin
  • Muhammad Yusoff Mohd Ramdzan
  • Jamil Aiman Mohd Baharudin




The paediatric population constitutes a much smaller proportion of COVID-19 patients and seems to be less severely affected. However, the massive numbers of COVID-19 infections mean that many children require treatment in hospital. In the concerted and wide-ranging effort to discover a safe and effective treatment for COVID-19, paediatric involvement is necessary. This review aims to identify leading potential drug treatments and vaccines for COVID-19 that are being investigated with children involved. Clinicaltrials.gov, WHO Trial Registry Platform (ICTRP) and RAPS COVID-19 vaccine tracker webportals were searched for clinical trials in phase 3 that involved children below 15 years of age. Any preliminary results released were searched online. The review found 25 phase 3 drug trials with paediatric participants and 2 vaccine trials. No preliminary findings were found. Remdesivir appears to be a leading candidate drug treatment and 2 vaccines candidates, inactivated nCoV-19 (Sinopharm) and ChAdOx1 (Oxford University), are recruiting children in large phase 3 trials. No treatments are currently licensed for COVID-19 but results from numerous trials are eagerly awaited.


Download data is not yet available.


DOI: 10.33102/mjosht.v6iSpecial Issue.123
Published: 2021-01-31

How to Cite

Nor Aripin, K. N., Mohd Ramdzan, M. Y., & Mohd Baharudin, J. A. (2021). A Rapid Review of Potential Drug Treatments for Children with COVID-19. Malaysian Journal of Science Health & Technology, 6(Special Issue). https://doi.org/10.33102/mjosht.v6iSpecial Issue.123



Integration of Science & Technology